Navigation Links
Joslin launches national study to explore if anti-inflammatory drug can treat type 2 diabetes
Date:1/21/2009

, nearly 24 million people have diabetes. Type 2 diabetes accounts for about 90 to 95 percent of diagnosed cases, representing nearly 10 percent of the adult population. Type 2 diabetes, previously called adult onset or non-insulin dependent diabetes, is a disorder in which muscle and fat cells do not use insulin properly. Type 2 diabetes is closely linked to obesity and puts people who have the disease at greater risk for complications, including cardiovascular disease, blindness, kidney disease and amputations. People with type 2 diabetes die at rates two- to four-times higher than those who do not have diabetes.

"Sedentary lifestyle and western diet have been associated with obesity and diabetes," says co-principal investigator Allison B. Goldfine, M.D., Director of Clinical Research at Joslin and Associate Professor of Medicine at Harvard Medical School. "The study medication, salsalate, which is chemically similar to aspirin but has fewer side effects, has been used for more than 40 years in people to treat pain associated with arthritis. Recent studies in people show that salsalate also lowers blood glucose, but further testing on long-term efficacy and safety specifically in patients with diabetes needs to be done."

"The outcome of this study has the potential for significant public health benefit," said Myrlene Staten, M.D., NIDDK's Senior Advisor for Diabetes Translational Research. "If salsalate improves the control of type 2 diabetes, we would have an inexpensive addition to our arsenal of drug options."

In previous studies Drs. Shoelson and Goldfine and their collaborators found that inflammation an immune system response that normally fights infection and promotes healing plays a major role in the development of insulin resistance and type 2 diabetes. These researchers were the first to show that a major trigger of inflammation the transcription factor NF-kB is activated in fat, liver, and other tissues of the body,
'/>"/>

Contact: Kira Jastive
kira.jastive@joslin.harvard.edu
617-732-2418
Joslin Diabetes Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Joslin study finds restricting insulin doses increases mortality risk
2. Joslin researcher named first winner of the Manpei Suzuki International Prize for Diabetes Research
3. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
4. UPMC Health Plan Launches New Personal Health Record
5. HealthInsuranceFinders.com Launches Video Contest for Young Directors
6. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
7. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
8. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
9. Mannatech Launches Phase One of New Sales and Training Tools
10. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
11. Actavis Launches Carvedilol Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... North ... California in the fall of 2015 . These seventeen courses are pre-approved ... , Optimizing Functional Mobility in the Older Adult , August 22, ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for Invisalign. Invisalign is a revolutionary orthodontic treatment that allows patients to straighten ... Mozafari’s expertise and 3D computer imaging technology. You wear each set of aligners ...
(Date:7/27/2015)... ... 28, 2015 , ... Dr. Robert G. Schwartz , principal of Greenville, ... with Realief Neuropathy Centers in order to offer his patients a new system of ... of peripheral neuropathy. , Peripheral neuropathy is a disease caused by damage to the ...
(Date:7/27/2015)... ... July 28, 2015 , ... Conducting Advanced Root ... to Improve the Quality of Investigations , **Presented by FDAnews and Learning Plus**, ... CAPAs have been the #1 reason for 483 observations since 1997! , The ...
(Date:7/27/2015)... , ... July 28, 2015 , ... The National ... inductee into the NAPW VIP Woman of the Year Circle. She is recognized with ... 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for professional ...
Breaking Medicine News(10 mins):Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 2Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 3Health News:FDAnews Announces: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 16-17, 2015, Raleigh, NC 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2
... Still Has No System to Monitor MRSA in ... WASHINGTON, Dec. 3 A new study published ... Emerging Infectious,Diseases links a new strain of methicillin-resistant ... more than 20 percent of all human MRSA,infections ...
... LipoScience, Inc. is pleased to,announce the election of ... Mr. Landon has over 30 years of broad, multi-functional ... management, Mr. Landon,was Vice President & General Manager of ... for all of DuPont,s Medical,Products businesses, with total sales ...
... Neuro Kinetics, Inc., (http://www.neuro-kinetics.com ), manufacturers ... for balance, vestibular and neurological disorder,tests, ... has been appointed clinical director,audiology., ... testing, coordination of multi-,site research projects, ...
... Oncology (ESMO) is calling on European politicians to voice their ... receive the best possible treatment. , At a meeting ... States met in Brussels to consider the status of medical ... Such recognition is an essential step in providing optimal treatment ...
... with stimulants, antidepressants and other psychiatric drugs is ... lack of clinical practice guidelines. In a first ... professionals from the Bradley Hasbro Childrens Research Center ... specific disorders to help clinicians who are considering ...
... beat out college students in tests involving digits 1 through ... -- It may be a case of monkey see, monkey ... human adults at remembering numbers. , A team of Japanese ... had learned how to identify the numbers 1 through 9 ...
Cached Medicine News:Health News:New Study Links Animal Agriculture to More Than 20% of MRSA Infections in the Netherlands 2Health News:Neuro Kinetics Appoints Dr. Terri Ives Clinical Director, Audiology 2Health News:Cancer patients to be treated by qualified professionals 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Chimps Top Humans in Number Recall 2
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
(Date:7/27/2015)... IRVINE, Calif. , July 27, 2015 ... ELOS ) , a global market leader in ... has received Korean Ministry of Food and Drug Safety ... this regulatory clearance, the Company can fulfill PicoWay orders ... activity in Korea anticipated later in the third quarter ...
(Date:7/27/2015)... YORK , July 27, 2015  Relmada ... novel therapies for the treatment of chronic pain, ... Trial Application (CTA) with Heath Canada ... study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ... of neuropathic pain. "We are very ...
Breaking Medicine Technology:Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 2Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 3
... NEW YORK, June 3 Delcath Systems, Inc.,(Nasdaq: ... Center of,Bethlehem, PA, part of St. Luke,s Hospital & ... trial for the treatment of,inoperable metastatic melanoma in the ... the isolated, high dose,delivery of the anti-cancer agent melphalan. ...
... Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit ... ... Calif., June 3 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... antitumor activity in a Phase 2,trial when administered in combination with ...
Cached Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6
Silicone Elastomer-Coated Latex Foley Catheters 2-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
... The BladderScan® BVI 6300 Bladder Monitor ... prescribed by the healthcare provider to ... on an ongoing basis. It is ... accurate results, so the patient can ...
Medicine Products: